Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Unwavering Benefits of Statins
Statins and the Development of Diabetes
WOSCOPS Pravastatin Reduction in LDL-C/Reduced CAD by 30%
JUPITER Rosuvastatin Therapy and Diabetes Risk
The Nudge Into T2D
Key Factors for Risk Reduction
Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID)
LIPID Results Summary
Pitavastatin Head-to-Head Statin Trials
REAL-CAD
Baseline Characteristics
Primary Endpoint (CV Death/MI/Ischemic Stroke/UA)
Serial Changes in Lipid Parameters and hs-CRP
Safety Outcomes
Pitavastatin Has Neutral Effect on FBG Across Dose Range
Potential Mechanism at Play
Application to Various Populations
Main Take-Home Messages
Patients With Risk Factors Need Education
Patient Education Team Approach
Final Thought
Abbreviations
Abbreviations (cont)